SLC5A2 and chronic kidney disease: Sodium/glucose cotransporter 2 (SGLT2) inhibitors in combination with inhibitors of the renin angiotensin aldosterone system have been shown to be of value in preventing kidney failure in patients with chronic kidney disease (CKD) (114, 115).